ELI LILLY AND COMPANY Stock Repurchase Program, Authorized Amount
ELI LILLY AND COMPANY (LLY) had Stock Repurchase Program, Authorized Amount of $5.00 billion as of 2021-05-31, per its 10-Q filed 2024-04-30.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramAuthorizedAmount1 · last filed 2024-04-30
- 2021-05-31: Stock Repurchase Program, Authorized Amount $5.00B.
- 2018-09-30: Stock Repurchase Program, Authorized Amount $8.00B.
- 2018-06-30: Stock Repurchase Program, Authorized Amount $8.00B.
- 2013-10-31: Stock Repurchase Program, Authorized Amount $5.00B.
| Period end | Stock Repurchase Program, Authorized Amount |
|---|---|
| 2021-05-31 | $5.00B 10-Q · filed 2024-04-30 |
| 2018-09-30 | $8.00B 10-Q · filed 2020-10-28 |
| 2018-06-30 | $8.00B 10-K · filed 2022-02-23 |
| 2013-10-31 | $5.00B 10-Q · filed 2018-04-27 |
| 2012-12-31 | $1.50B 10-Q · filed 2014-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |